抗药性
类有机物
精密医学
个性化医疗
微流控
结直肠癌
表型筛选
计算生物学
克拉斯
药品
表型
精确肿瘤学
微流控芯片
药物发现
癌症研究
医学
药物开发
癌症
药物反应
生物信息学
数字聚合酶链反应
循环肿瘤细胞
靶向给药
药物输送
结直肠癌筛查
合成致死
生物
抗癌药物
功效
液体活检
靶向治疗
基因组学
作者
Dongguo Lin,Yanzhang Luo,Jueming Chen,Ziqing Ma,Hui Kang,X. Wang,Lihui Wang,Dayu Liu
标识
DOI:10.1038/s41378-025-01068-1
摘要
Tumor heterogeneity drives chemotherapy resistance in cancer, necessitating the development of strategies to target diverse cellular subpopulations. Single-cell-derived tumor organoids (STOs), derived from individual tumor stem cells (TSCs), retain well-defined genomic and phenotypic attributes, making them instrumental in elucidating unique diversification. Here, we developed a microfluidic approach that utilizes STO arrays for personalized drug screening, aimed at overcoming heterogeneity induced drug resistance in colorectal cancer. We utilized a microwell array format microfluidic chip to the generation of a high scale STO array. This array encompasses two key features: (1) STOs in individual microwells are derived from single TSCs, which allows for a high-resolution display of cellular heterogeneity; (2) it exhibits thousands of STOs at predefined locations on the same focal plane, thereby facilitating automated, high-content analyses using imaging data. Utilizing the STO array, we assess the responses of various subpopulations of colorectal cancer to a conventional chemotherapeutic regimen, facilitating the phenotypic identification of resistant STOs. Through the analysis of RNA sequencing data from the resistant STOs, candidate drugs targeting resistance-associated pathways were identified for individual patients. Furthermore, the candidate drugs were validated through STO-array drug testing, demonstrating enhanced clearance effects when combined with the conventional regimen. Our study establishes a scalable, patient-specific drug screening approach that integrates phenotypic and molecular analyses, offering a transformative strategy to overcome heterogeneity-driven drug resistance in colorectal cancer. The microfluidic platform presented herein holds significant potential for advancing precision oncology and personalized therapeutic design.
科研通智能强力驱动
Strongly Powered by AbleSci AI